Genmab's Darzalex Faspro (daratumumab and hyaluronidase-fihj) Receives the US FDA's Approval for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
Shots:
- The approval is based on P-III ANDROMEDA (AMY3001) study involves assessing of Darzalex Faspro + bortezomib- cyclophosphamide- and dexamethasone (VCd) vs VCd alone in 388 patients with newly diagnosed AL amyloidosis
- Genmab to receive $30M as milestones with the first commercial sale of Darzales faspro in this indication. The US FDA reviewed the submission of data for approval in this indication under RTOR pilot program and Project Orbis
- Darzalex faspro is the SC formulation of daratumumab and is the only therapy for newly diagnosed Light-chain (AL) amyloidosis in the US
Ref: GlobeNewswire | Image: Genmab
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
